ACADIA Pharmaceuticals (MEX:ACAD) Other Gross PPE: MXN0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MEX:ACAD ACADIA Pharmaceuticals Inc MEX:ACAD
75 GF Score
Price MXN499.00
GF Value MXN356.46
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is ACADIA Pharmaceuticals Other Gross PPE?

ACADIA Pharmaceuticals MEX:ACAD 75 Other Gross PPE is MXN0 Mil as of Jun. 2026. GuruFocus rates MEX:ACAD with a GF Score™ of 75/100 and a GF Value™ of MXN356.46 (Significantly Overvalued). The stock has 10 warning signs investors should review.

ACADIA Pharmaceuticals's Other Gross PPE for the quarter that ended in Jun. 2026 was MXN0 Mil.

ACADIA Pharmaceuticals's quarterly Other Gross PPE declined from Dec. 2025 (MXN1,098 Mil) to Mar. 2026 (MXN0 Mil) but then stayed the same from Mar. 2026 (MXN0 Mil) to Jun. 2026 (MXN0 Mil).

ACADIA Pharmaceuticals's annual Other Gross PPE increased from Dec. 2023 (MXN1,118 Mil) to Dec. 2024 (MXN1,258 Mil) but then declined from Dec. 2024 (MXN1,258 Mil) to Dec. 2025 (MXN1,098 Mil).

ACADIA Pharmaceuticals Other Gross PPE Historical Data

* Premium members only.

The historical data trend for ACADIA Pharmaceuticals's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ACADIA Pharmaceuticals Other Gross PPE Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Gross PPE
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,481.38 1,358.09 1,118.07 1,257.55 1,098.31

ACADIA Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Gross PPE Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 1,098.31 0.00 0.00
MEX:ACAD
75GF Score
ACADIA Pharmaceuticals Inc MEX:ACAD
Other Gross PPE is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ACADIA Pharmaceuticals Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Frequently Asked Questions Learn more about Other Gross PPE →
What does a Other Gross PPE of MXN0 Mil mean?
ACADIA Pharmaceuticals (MEX:ACAD) has a Other Gross PPE of MXN0 Mil as of Jun. 2026. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on ACADIA Pharmaceuticals and its competitors.
Is ACADIA Pharmaceuticals' Other Gross PPE too high?
ACADIA Pharmaceuticals' current Other Gross PPE is MXN0 Mil. Overall, ACADIA Pharmaceuticals has a GF Score™ of 75/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ACADIA Pharmaceuticals' Other Gross PPE compare to PBLS and DYN?
ACADIA Pharmaceuticals' Other Gross PPE of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Gross PPE for a Biotechnology company?
A good Other Gross PPE depends on the Biotechnology industry context. However, Other Gross PPE should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Gross PPE mean?
A high Other Gross PPE can signal that a stock is expensive relative to its fundamentals. Other Gross PPE is property, plant and equipment recorded on a company's balance sheet that not otherwise classified. View historical data on ACADIA Pharmaceuticals and its competitors. ACADIA Pharmaceuticals's current Other Gross PPE is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ACADIA Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, ACADIA Pharmaceuticals (MEX:ACAD) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN356.46, compared to a current price of MXN499.00 — trading 40% above its estimated fair value. The current Other Gross PPE is MXN0 Mil. ACADIA Pharmaceuticals' overall GF Score™ is 75/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Gross PPE calculated?
Other Gross PPE is calculated from a company's financial statements. For ACADIA Pharmaceuticals (MEX:ACAD), the current Other Gross PPE is MXN0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ACADIA Pharmaceuticals (MEX:ACAD) Overvalued in 2026?

Based on GuruFocus' analysis, ACADIA Pharmaceuticals stock appears to be overvalued. The current stock price of MXN499.00 is trading 40% above its estimated GF Value™ of MXN356.46. GuruFocus considers ACADIA Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for MEX:ACAD:

  • Other Gross PPE: MXN0 Mil
  • GF Value™: MXN356.46 vs. price of MXN499.00 (40% above fair value)
  • GF Score™: 75/100 with 10 warning signs

No single metric tells the full story. See the MEX:ACAD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ACADIA Pharmaceuticals Business Description

Other Exchanges ACAD:USADR6:Germany
Address 12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-211, ACP-711, ACP-2591, etc.
75GF Score

Get the complete analysis for MEX:ACAD

Other Gross PPE is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN499.00
Price
MXN356.46
GF Value